AAT Augmentation denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for aat augmentation are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies AAT Augmentation as Non-Formulary

Alpha-1 antitrypsin augmentation products are high-cost specialty biologics that Blue Cross Blue Shield plans frequently place on a non-preferred or excluded formulary tier. A non-formulary denial means the plan's pharmacy benefit does not list the specific product at a covered tier — not that the therapy is clinically inappropriate. Because AAT augmentation is the only FDA-approved pharmacological treatment specifically indicated for AAT deficiency-related lung disease, a non-formulary denial is particularly vulnerable to appeal on the grounds that no therapeutically equivalent formulary alternative exists.

## Why This Is Appealable

ACA §2719 and ERISA §503 require that non-formulary denials for drugs with no clinically appropriate formulary substitute be subject to a meaningful exceptions process. If BCBS's formulary lacks any alternative indicated for your specific condition (hereditary AAT deficiency), the standard "use the formulary alternative first" rationale does not apply. Your appeal should establish that fact explicitly. External review is available after exhausting internal appeals, with a four-month window to request it.

## Documentation to Gather

• Prescriber letter on lack of alternatives: A letter from your physician explaining that no formulary-listed drug is indicated for AAT deficiency-related lung disease and that a formulary exception is therefore required as a matter of medical necessity.
• Diagnosis confirmation: Laboratory phenotype/genotype documentation confirming hereditary AAT deficiency.
• Formulary exception request: A formal written formulary exception request submitted to BCBS citing the absence of a therapeutically equivalent covered alternative.
• Prior authorization records (if any): Any prior correspondence with BCBS about this therapy.

## Criteria-Mapping Structure

Review BCBS's published formulary exception policy (available in your plan documents or by calling member services and requesting the medical policy). List each condition BCBS requires for a formulary exception in a left column. In the right column, document exactly how your case satisfies each condition — in particular, the absence of a covered therapeutic alternative and the clinical necessity of the specific product prescribed. Attach supporting records as exhibits.

## Timeline

1. Submit internal appeal and/or formulary exception request promptly — within 180 days of the denial notice. 2. BCBS must respond within 30 days for pre-service requests. 3. After final internal denial, request independent external review within 4 months.